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RESUMEN

Con los avances en imaginología, es posible una detección más temprana de las recidivas y las enfermedades metastásicas. Sin embargo, los datos existentes acerca del patrón de metastásico del cáncer de vejiga, son limitados. Además, las metástasis cutáneas de las malignidades genitourinarias primarias son raras, y a pesar de los avances en la obtención de imágenes
INTRODUCTION
Bladder carcinoma is one of the common malignant diseases but data on its metastatic pattern are limited. One should be familiar with the common and uncommon sites of metastases as their detection is important to guide appropriate treatment selection and has a marked influence on prognosis. The incidence of cutaneous metastases from all urologic malignancies is 1.1% to 2.5% (1). Metastases to the skin from renal cell carcinoma are the most common (3.4% to 4.0%), and negativity for CK5/6, placental alkaline phosphatase (PLAP), napsin, thyroid transcription factor-1 (TTF-1), cluster of differentiation (CD) 117 and homeobox protein CDX-2. A diagnosis of undifferentiated carcinoma favouring metastatic urothelial carcinoma was made. Work-up for haematuria showed a large bladder mass with bilateral hydroureteronephrosis (Fig. 6 ). There was a large liver mass suspicious for a metastatic lesion. In addition, there were multiple right adrenal masses, peritoneal nodules, largest in the left subphrenic region, several other smaller soft tissue nodules in the posterior abdominal wall and gluteal region, and bilateral axillary, pelvic and inguinal lymphadenopathy.
Serum creatinine and blood urea nitrogen (BUN) levels were elevated (2.2 mg/dL and 23 mg/dL, respectively). Hyperkalaemia (serum potassium 5.9 mg/dL) and deranged serum protein profile were noted. Serum alpha fetoprotein (AFP) levels were normal and mild elevation of gammaglutamyl transpeptidase (GGT) was noted (113 U/L). Serum Bilateral ureteric stents were inserted. Later, transurethral resection of bladder tumour (TURBT) for the bladder mass and the flank mass resection were done (Fig. 7) .
were transfused and there was some improvement in the patient's haemoglobin levels. The patient received one cycle of chemotherapy including gemcitabine, cisplatin and carboplatin; however, he died seven weeks after receiving the chemotherapy and 17 weeks after the initial presentation.
DISCUSSION
Chung et al described a case of urothelial carcinoma of the bladder that metastasized to the brain and abdominal skin (3). Akman et al have described a rare case of extensive skin metastases of transitional cell carcinoma as the initial presenting feature (4). Chang et al reported a patient with bladder urothelial carcinoma presenting with cutaneous metastases initially and bladder tumour was the incidental finding (5). Shinagare et al have published a study that evaluated the metastatic pattern of muscle invasive bladder cancer from a clinic population of 392 patients. The most common sites were lymph nodes (69%), bone (47%), lung (37%), liver (26%), peritoneum (16%), pleura (11%), soft tissue including subcutaneous tissue (9%), adrenal (7%), brain (5%), urethra (3%), intestine (3%) and spleen [1%] (6) .
Cutaneous metastasis from internal malignancies is a rare clinical entity and may be the first sign of an advanced disease. In a meta-analysis performed by Krathen et al, it was found that the overall incidence of cutaneous metastases was 5.3% among 20 380 cancer patients (7). Breast cancer was the most common origin of cutaneous metastases and the most common affected sites were the chest and the abdomen. Due to the limited number of patients with cutaneous metastases of bladder cancer and their subsequent poor survival, management strategies have not been clearly defined. Treatment options are often limited and palliative due to the patient's advanced age and the disease stage, resulting in poor prognosis. The treatment of choice for metastatic bladder cancer is chemotherapy, which is rarely curative. Currently, the combination of gemcitabine and cisplatin and the MVAC scheme (methotrexate, vinblastine, doxorubicin and cisplatin) are established treatments with reported tumour remission rates up to 70% (8, 9) . Prognosis, however, is poor.
In conclusion, we presented a rare case of cutaneous metastases from urothelial carcinoma of the bladder. Metastatic disease should always be considered in the differential diagnosis in patients who present with malignant appearing skin nodules and a search should be done to identify the primary tumour, if not diagnosed previously. Urothelial carcinoma, although rare, can be a source of metastasis to the subcutaneous tissues. Due to advanced stage of the disease in most cases, treatment is mainly supportive and the prognosis is poor.
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